Description
Biofinity® multifocal is a monthly replacement silicone hydrogel contact lens for patients with presbyopia*.
Features and Benefits
- Balanced Progressive® Technology for clear vision at all distances1
- Two different optical designs (D and N) for individualised fitting for each wearer and each eye.1
- High-contrast distance and near visual acuity for 20/20 (or 6/6)2
- Highly effective fitting process - fit 98% of your patients with two pairs of lenses3
- Aquaform® Technology for incredible all-day comfort1
- Naturally wettable material with no need for surface treatments or coatings1
- The widest silicone hydrogel prescription range that covers 99.7% of (single vision) presbyopes‡4,5
- Designed by a world leader in multifocal contact lenses†1
- Suitable for overnight wear of up to 6 nights and 7 days.6
| Aquaform® TechnologyAquaform® Technology allows water to be held throughout each Biofinity® lens material, from its core to its surface, helping to keep it moist all day long.1 This provides natural wettability, without coatings or surface treatments to support an incredibly comfortable lens-wearing experience.1 |
| Balanced Progressive® Technology
|
Product Details
-6.00 to plano (0.25D steps)
+0.25 to +6.00DS (0.25D steps)
D-Design (dominant eye)
N-Design (non-dominant eye)
Packaging images for illustration purposes only.
* With myopia, hyperopia or emmetropia with presbyopia.
† Combination of 2023 market research based on global volume data and internal estimates. Does not include CooperVision specialty eyecare products.
‡ Based on Rx option combinations (sphere, cylinder, axis & add) manufactured, across all soft lenses in sphere, toric & multifocal (including made to order), in SiHy from 4 main manufacturers. Includes one-day, 2 weekly, and monthly replacement contact lenses. Cosmetic & Photochromatic contact lenses not included. Multiple base curve variants not included.
References:
1. CVI data on file, 2024.
2. Fernandes P et al. Adaptation to multifocal and monovision contact lens correction. Optom Vis Sci. 2013 Mar;90(3):228-35.
3. CVI data on file 2019. Retrospective analysis; N=55 subjects (110 eyes); DV Rx +1.25D to -3.25D, add powers +1.25 to +2.50DS.
4. CVI data on file, 2023. Industry reports and internal estimates based on Tyler's Quarterly, 12/2022.
5. CVI data on file, 2020. Rx coverage database; 42 to 70 years <0.75DC.
6. A.M. Moezzi, et al. Overnight Corneal Swelling, CLAO; 32(6): 277–280.
For the device safety, warnings, precaution, and local regulatory information, please refer to the Instruction for Use leaflet.
SA13068 / APP135596